Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital
Cambridge, CB2 0QQ, United Kingdom
NCT Number: NCT03609528
The CamPROBE study investigates the rate of infective complications using the Cambridge Prostate Biopsy Device method of local anaesthetic transperineal prostate biopsies.
Looking for future studies?
Notify Me18 year and older
Male
Interventional
Not applicable
Cambridge, CB2 0QQ, United Kingdom
The current method for diagnosing prostate cancer requires a biopsy needle to pass through the bowel wall to reach the prostate. Bacteria in the bowel inevitably enter the urinary system and blood stream. A significant number of men develop infections despite preventative antibiotics (1 in 10 develop fevers/shivers and 1-2 in 100 get a life-threatening infection). It is crucial we find a safer biopsy method for suspected prostate cancer as over 1 million rectal biopsies occur each year.
A safer alternative device was developed, performed under local anaesthetic using the transperineal route: CamPROBE (Cambridge Prostate Biopsy Device). CamPROBE biopsies are taken through the perineum (the area under the testicles), so there is no infection risk, and it's just as good at diagnosing prostate cancer. This investigation progresses from a prototype to a disposable, single use device that any UK hospital can use. The study will assess CamPROBE's ability to reduce infections from prostate biopsies and its usability as an alternative to the current standard biopsies.
Men recommended to undergo a prostate biopsy will be eligible for this multi-centre study. For each patient, the study will take approximately 30 days, consisting of: recruitment, 1 day for the procedure (replaces the standard biopsy pathway) and questionnaires on day 1, 7 and 30. This timeframe will not introduce delays in the patients' normal standard care pathway. Patients will have a transperineal biopsy with CamPROBE instead of the current transrectal method. Biopsy samples will be treated the same as standard procedure. Patients' acceptability of the procedure and complications will be measured using patient self-reported questionnaires.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
To be included in the clinical investigation the participant must:
Exclusion criteria
The presence of any of the following will preclude participant inclusion:
To be completed
Time frame: 30 days post biopsy
Changes in incidence of infection as measured using patient self-reported Follow-Up Questionnaires and telephone assessments.
Time frame: 30 days post biopsy
Patient reported pain scores as measured using patient self-reported questionnaires.
Time frame: 30 days post biopsy
Patient biological functions as measured using patient self-reported questionnaires
Time frame: 30 days post biopsy
Patients' willingness to have a repeat biopsy as measured using patient self-reported questionnaires
Time frame: 1 day
Clinician perception of the device and the performance of the CamPROBE assessed using Clinical Performance Assessment questionnaire
Cambridge University Hospitals NHS Foundation Trust
Other
Acronym: CamPROBE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04465214
Colon Cancer, Colonic Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06998121
Anxiety Disorders, Genital Diseases
Mersin, Turkey (Türkiye)
View Trial DetailsNCT05478239
Genital Diseases, Genital Diseases, Male
Lexington, Kentucky, United States
View Trial DetailsNCT07433140
Agnosia, Genital Diseases
Istanbul, Turkey (Türkiye)
View Trial Details